Navigation Links
Draining away brain's toxic protein to stop Alzheimer's
Date:8/13/2007

Scientists are trying a plumbers approach to rid the brain of the amyloid buildup that plagues Alzheimers patients: Simply drain the toxic protein away.

Thats the method outlined in a paper published online August 12 by Nature Medicine. Scientists from the University of Rochester Medical Center show how the bodys natural way of ridding the body of the substance is flawed in people with the disease. Then the team demonstrated an experimental method in mice to fix the process, dramatically reducing the levels of the toxic protein in the brain and halting symptoms. The team is now working on developing a version of the protein that could be tested in people with the disease.

The approach doesnt take direct aim at the pathology that is ubiquitous in the Alzheimers patients brains, where amyloid-beta forms a toxic plaque. Instead, researchers take an indirect approach, focusing not on the brain but rather on a protein that sops up amyloid-beta in the body, where its regarded as harmless. The scientists found that if they increase the bodys ability to soak up amyloid, the brain responds, causing levels of the substance in the brain the real target to plummet.

There is a dynamic equilibrium between the levels of amyloid-beta in the blood and in the brain, said neuroscientist Berislav Zlokovic, M.D., Ph.D., the leader of the team. If we are able to lower the levels of amyloid-beta circulating in blood by sequestering more of it there, then the brain should follow and lower its levels too. This is exactly what we found.

The team concentrated its efforts around a protein known as sLRP (soluble low-density lipoprotein receptor-related protein). The team discovered that in healthy people, the protein binds to and neutralizes anywhere from 70 to 90 percent of the amyloid-beta that is circulating in the body.

The team also found that sLRP is doing only a fraction of the job in Alzheimers patients that it does in healthy people. Levels of sLRP in people with Alzheimers were about 30 percent lower than in healthy people, and the sLRP that was present was almost three times as likely to be damaged compared to the same protein in healthy people. As a result, the Alzheimers patients had on average three to four times as much loose, unbound amyloid-beta floating in their bloodstreams high levels that would likely also be reflected in the brain.

Zlokovics group decided to try to reduce amyloid-beta levels in the body by synthesizing an altered, super-potent form of sLRP that binds amyloid-beta more efficiently than natural sLRP. In blood samples from patients with Alzheimers disease, the modified version of sLRP, known as LRP-IV, soaked up and virtually eliminated amyloid-beta. The compound had an even more dramatic effect in mice with features of Alzheimers disease: LRP-IV lowered the levels of amyloid-beta in their brains by 85 to 90 percent. The mice that received the compound also had improved learning and memory compared to mice that did not receive LRP-IV, and they had 65 percent more blood flow in their brains in response to brain stimulation a flick of their whiskers.

The team is now working with a company created by Zlokovic, Socratech, to create a form of LRP-IV that could be tested in people. Zlokovic hopes to have such a product ready for testing within two years.

Zlokovic, a scientist widely recognized for demonstrating that blood vessels, blood flow, and the blood-brain barrier are all central to the development of Alzheimers disease, likens the new approach to how statins help people with heart disease. Statins lower excess cholesterol in the bloodstream before the cholesterol can glom onto a blood vessel and cause problems with blood flow; in the same way, LRP-IV lowers amyloid-beta and indirectly lowers levels of amyloid-beta in the brain.

It was more than a decade ago that Zlokovic first identified LRP, a molecule that acts like an escort service in the brain, shuttling amyloid-beta out of the brain and into the body. The amyloid plaques that speckle the brains of Alzheimers patients are a hallmark of the disease, and where they come from and how to get rid of them has long been a focus of scientists.

We used to think that Alzheimers disease was a problem with the production of too much amyloid-beta, but its become clear in recent years that the problem is with faulty clearance of amyloid-beta, said Zlokovic, professor of Neurosurgery and Neurology and director of the Frank P. Smith Laboratory for Neuroscience and Neurosurgery Research. We arent really talking about massive amounts of amyloid-beta. Even a small malfunction in the elaborate system that carries it into or out of the brain could lead, over years, to accumulate in amounts that damage the brain.


'/>"/>
Contact: Tom Rickey
tom_rickey@urmc.rochester.edu
585-275-7954
University of Rochester Medical Center
Source:Eurekalert

Related medicine news :

1. Babies Brains Are more Fragile
2. Genetic differences found between Male and Female brains
3. Fish eaters found to have sharper brains
4. Healthy Brains Depend Upon Survival Genes
5. Human neurons grown in the brains of mice
6. Hamsters Shows How Our Brains May Recognize Other Individuals
7. Brainstorming session for Bihar legislators on AIDS
8. Structural Abnormalities in Brains of William Syndrome Patients
9. Perception Stabilized – Thanks to Your Brains
10. Brain-child of Natus Medical, “Cool Cap”, Protects Brains of Babies Born With HE
11. Severe PTSD Damages Childrens Brains: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For ... their lives in military battle for the country. The nonprofit Hope For Heroes ... more programs that empower independence for disabled military veterans, as well as police, firemen, ...
(Date:5/26/2016)... ... 2016 , ... Cardiac arrhythmia is a common complication following ... survival, reports a team of UPMC researchers in the largest study of its ... Thoracic and Cardiovascular Surgery, provide critical information that will hopefully lead to better ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line ... in Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than ... by government agencies, including NASA. , In 2012, NASA strategically set up 17 ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James ... Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 pm at the ... founder of Retina Group of New York , is a Board Certified ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 Amarantus BioScience ... on developing products for Regenerative Medicine, Neurology and Orphan Diseases, today ... be presenting at two upcoming investor conferences: SeeThru ... Third Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
Breaking Medicine Technology: